Compare INBK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | CCCC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 185.1M |
| IPO Year | N/A | 2020 |
| Metric | INBK | CCCC |
|---|---|---|
| Price | $23.81 | $2.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $23.25 | $12.20 |
| AVG Volume (30 Days) | 50.7K | ★ 2.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $17.05 | $1.21 |
| 52 Week High | $28.51 | $3.82 |
| Indicator | INBK | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 53.72 |
| Support Level | $23.52 | $2.30 |
| Resistance Level | $24.85 | $3.20 |
| Average True Range (ATR) | 0.94 | 0.22 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 61.69 | 58.09 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.